RadNet's DeepHealth AI tool can help avoid nearly 1 in 5 prostate biopsies while maintaining high cancer detection sensitivity.
Key Details
- 1DeepHealth AI's risk-classification tool was compared to radiologist-assigned PI-RADS scores using multiparametric MRI.
- 2The AI-assisted approach avoided approximately 19% of prostate biopsies.
- 3Sensitivity for detecting clinically significant prostate cancer remained at 98.4%.
- 4Research published in European Radiology highlights the tool's value in uncertain MRI findings.
- 5The solution offers additional evidence to support clinician decision-making, with final biopsy decisions remaining clinical.
Why It Matters
Avoiding unnecessary prostate biopsies reduces patient risk, inconvenience, and healthcare costs. Radiology AI solutions like this promise improvements in efficiency, accuracy, and a more evidence-based biopsy decision process.
Source
Radiology Business
Related News
•Radiology Business
FDA Clears MRI2CT AI for 3D Bone Visualization from MRI
MRI2CT's NextMR receives FDA clearance to generate 3D bone images from standard spine MRIs, reducing reliance on CT scans.
•Radiology Business
FDA Clears AIRS Medical AI for Rapid MRI Body Composition Analysis
AIRS Medical's SwiftSight Body Composition AI software receives FDA 510(k) clearance for automated MRI-based body composition reporting.
•Radiology Business
Multi-Vendor AI Adoption Delivers Efficiency Gains in Private Radiology
A large-scale European study shows that adopting multiple AI tools in private radiology practices leads to significant efficiency improvements.